EyePoint Pharmaceuticals, Inc. Common Stock
EYPT
EYPT: EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.
moreShow EYPT Financials
Recent trades of EYPT by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by EYPT's directors and management
Government lobbying spending instances
-
$80,000 Jan 15, 2023 Issue: Medicare/Medicaid Health Issues
-
$80,000 Oct 17, 2022 Issue: Medicare/Medicaid Health Issues
-
$80,000 Jul 16, 2022 Issue: Medicare/Medicaid Health Issues
-
$80,000 Apr 15, 2022 Issue: Medicare/Medicaid Health Issues
-
$80,000 Jan 17, 2022 Issue: Medicare/Medicaid Health Issues
-
$80,000 Oct 17, 2021 Issue: Health Issues Medicare/Medicaid
-
$80,000 Jul 17, 2021 Issue: Medicare/Medicaid Health Issues
-
$80,000 Apr 19, 2021 Issue: Health Issues Medicare/Medicaid
-
$90,000 Jan 20, 2021 Issue: Budget/Appropriations Medicare/Medicaid Health Issues
-
$90,000 Oct 19, 2020 Issue: Budget/Appropriations Medicare/Medicaid Health Issues
-
$90,000 Jul 19, 2020 Issue: Health Issues Medicare/Medicaid
-
$90,000 Apr 19, 2020 Issue: Health Issues Medicare/Medicaid
-
$10,000 Oct 21, 2019 Issue: Health Issues
-
$20,000 Jul 17, 2019 Issue: Health Issues
-
$20,000 Apr 22, 2019 Issue: Health Issues
New patents grants
-
Patent Title: Methods of treating intraocular pressure with activators of tie-2 Jun. 06, 2023
-
Patent Title: Small molecule activators of tie-2 Mar. 28, 2023
-
Patent Title: Formulations of tie-2 activators and methods of use thereof Aug. 16, 2022
-
Patent Title: Bioerodible drug delivery devices Apr. 12, 2022
-
Patent Title: Tie-2 activators targeting the schlemm's canal Feb. 22, 2022
-
Patent Title: Humanized monoclonal antibodies that target ve-ptp (hptp-beta) Nov. 23, 2021
-
Patent Title: Bioerodible silicon-based devices for delivery of therapeutic agents Jun. 08, 2021
-
Patent Title: Injector apparatus Jul. 30, 2019
-
Patent Title: Ocular inserter Jun. 18, 2019
-
Patent Title: Bioerodible sustained release drug delivery systems May. 28, 2019
Federal grants, loans, and purchases
Followers on EYPT's company Twitter account
Number of mentions of EYPT in WallStreetBets Daily Discussion
Recent insights relating to EYPT
Recent picks made for EYPT stock on CNBC
ETFs with the largest estimated holdings in EYPT
Flights by private jets registered to EYPT